What is HC Wainwright’s Estimate for OmniAb Q1 Earnings?

OmniAb, Inc. (NASDAQ:OABI) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for OmniAb in a report released on Wednesday, March 19th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.15) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for OmniAb’s Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.57) EPS, FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.37) EPS and FY2028 earnings at ($0.27) EPS.

OmniAb (NASDAQ:OABI) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. OmniAb had a negative return on equity of 20.97% and a negative net margin of 308.78%. The firm had revenue of $10.80 million during the quarter, compared to the consensus estimate of $10.13 million. During the same period in the prior year, the business earned ($0.14) EPS.

Separately, Benchmark reduced their target price on shares of OmniAb from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, March 20th.

OmniAb Stock Performance

Shares of OABI opened at $2.54 on Monday. The firm has a fifty day moving average of $3.33 and a 200-day moving average of $3.75. The company has a market cap of $358.69 million, a price-to-earnings ratio of -4.10 and a beta of -0.14. OmniAb has a 1 year low of $2.23 and a 1 year high of $5.63.

Insider Buying and Selling at OmniAb

In other OmniAb news, insider Charles S. Berkman sold 25,489 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total transaction of $82,584.36. Following the sale, the insider now directly owns 343,190 shares in the company, valued at approximately $1,111,935.60. The trade was a 6.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Matthew W. Foehr sold 41,811 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total transaction of $135,467.64. Following the completion of the sale, the chief executive officer now directly owns 3,749,639 shares of the company’s stock, valued at approximately $12,148,830.36. This represents a 1.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 112,260 shares of company stock valued at $376,601 in the last quarter. Corporate insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On OmniAb

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OABI. Hsbc Holdings PLC bought a new position in OmniAb during the fourth quarter valued at about $38,000. Choreo LLC acquired a new stake in OmniAb in the 4th quarter valued at about $41,000. Rangeley Capital LLC bought a new position in shares of OmniAb during the 4th quarter valued at about $41,000. KLP Kapitalforvaltning AS bought a new position in shares of OmniAb during the 4th quarter valued at about $49,000. Finally, Walleye Capital LLC acquired a new position in shares of OmniAb in the 3rd quarter worth approximately $61,000. 72.08% of the stock is owned by institutional investors.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.